Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC9204-1177 · 2 trials · 4 indications
ng\*h/mL
ng\*h/mL
ng\*h/mL
ng\*h/mL
ng\*h/mL
| Arm | Type | Description |
|---|---|---|
| NNC9204-1177 and cocktail of approved drugs | EXPERIMENTAL | - |
| NNC9204-1177 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC9204-1177 | DRUG | Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks |
| Cocktail of 5 already approved drugs | DRUG | 5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study |
| Placebo | DRUG | A single dose administered subcutaneously ( s.c. under the skin) |
Inclusion Criteria: * Male or female, aged 18-60 years (both inclusive) at the time of signing informed consent. * Body mass index (BMI) between 23.0 and 29.9 kg/m\^2 (both inclusive) at screening. * Considered to be generally healthy based on the medical history, physical examination, and the resu...
NNC9204-1177 is an investigational small molecule being studied for metabolism and nutrition disorders, including obesity and overweight. It is in Phase 1 clinical development and has been evaluated in healthy volunteers and subjects who are overweight or have obesity.
NNC9204-1177 is being developed by Novo Nordisk A/S, a biopharmaceutical company listed on the stock exchange under the ticker NVO. The drug is in early-stage clinical development for metabolic conditions.
NNC9204-1177 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety, tolerability, and pharmacokinetics.
NNC9204-1177 has been studied in two completed Phase 1 trials. NCT02941042 investigated single doses in overweight or obese subjects, and NCT04059367 examined how the drug affects blood levels of other medicines in healthy people. Both trials were conducted in the United States.
NNC9204-1177 is the investigational name used in clinical trials for this drug candidate. No alternative names have been reported for this compound in the available clinical trial information.